Elanco Animal Health (ELAN) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Cover page

Cover page - shares	9 Months Ended
	Sep. 30, 2020	Nov. 02, 2020
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-38661
Entity Registrant Name	Elanco Animal Health Inc
Entity Incorporation, State or Country Code	IN
Entity Tax Identification Number	82-5497352
Entity Address, Address Line One	2500 INNOVATION WAY
Entity Address, City or Town	GREENFIELD
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46140
City Area Code	877
Local Phone Number	352-6261
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		471,915,051
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001739104
Current Fiscal Year End Date	--12-31
Common stock, no par value
Document Information [Line Items]
Title of 12(b) Security	Common stock, no par value
Trading Symbol	ELAN
Security Exchange Name	NYSE
5.00% Tangible Equity Units
Document Information [Line Items]
Title of 12(b) Security	5.00% Tangible Equity Units
Trading Symbol	ELAT
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 889.6	$ 771.3	$ 2,133.6	$ 2,284
Costs, expenses and other:
Cost of sales	441.8	360.4	1,070.4	1,060.2
Research and development	88.1	69.9	214.3	202.8
Marketing, selling and administrative	277.7	192.3	622.5	574.3
Amortization of intangible assets	95.6	50.7	196.2	149
Asset impairment, restructuring and other special charges (Note 7)	262.2	77.2	456.4	133.9
Interest expense, net of capitalized interest (Note 10)	48.1	18.7	89.4	60.2
Other–net, (income) expense	(114.9)	14.6	(161.7)	21.1
Costs, expenses and other	1,098.6	783.8	2,487.5	2,201.5
Income (loss) before income taxes	(209)	(12.5)	(353.9)	82.5
Income tax (benefit) expense	(74)	(22.5)	(116.6)	5.1
Net income (loss)	$ (135)	$ 10	$ (237.3)	$ 77.4
Earnings (loss) per share:
Basic (usd per share)	$ (0.29)	$ 0.03	$ (0.56)	$ 0.21
Diluted (usd per share)	$ (0.29)	$ 0.03	$ (0.56)	$ 0.21
Weighted average shares outstanding:
Basic (in shares)	462.4	371.6	426.5	367.7
Diluted (in shares)	462.4	373.2	426.5	368.7

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (135)	$ 10	$ (237.3)	$ 77.4
Other comprehensive income (loss):
Unrealized loss on derivatives for cash flow hedges, net of taxes	(7.5)	0	(67.4)	0
Foreign currency translation	101.2	(58.9)	121.5	(53.7)
Defined benefit pension and retiree health benefit plans, net of taxes	(0.7)	21.2	(2.2)	23.4
Other comprehensive income (loss), net of tax	93	(37.7)	51.9	(30.3)
Comprehensive income (loss)	$ (42)	$ (27.7)	$ (185.4)	$ 47.1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 659.9	$ 334
Accounts receivable, net of allowances of $8.8 (2020) and $6.2 (2019)	762.3	816.9
Other receivables	70.8	73
Inventories (Note 8)	1,597.1	1,050.7
Prepaid expenses and other	180.6	87.4
Restricted cash (Note 17)	10.7	11.1
Total current assets	3,281.4	2,373.1
Noncurrent Assets
Goodwill	6,434.7	2,989.6
Other intangibles, net (Note 6)	5,785.6	2,482.8
Other noncurrent assets	492.8	185
Property and equipment, net of accumulated depreciation of $982.7 (2020) and $930.5 (2019)	1,242.5	955.3
Total assets	17,237	8,985.8
Current Liabilities
Accounts payable	355.9	222.6
Employee compensation	139.9	99.6
Sales rebates and discounts	278.6	211
Current portion of long-term debt (Note 10)	553.6	24.5
Other current liabilities	531.9	244.4
Payable to Lilly (Note 17)	11.3	16.4
Total current liabilities	1,871.2	818.5
Noncurrent Liabilities
Long-term debt (Note 10)	5,586.5	2,330.5
Accrued retirement benefits	299.1	82.5
Deferred taxes	823.1	100.8
Other noncurrent liabilities	312.9	106.6
Total liabilities	8,892.8	3,438.9
Commitments and Contingencies (Note 14)	0	0
Equity
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued	0	0
Common stock, no par value, 5,000,000,000 shares authorized, 471,879,904 and 373,011,513 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	0	0
Additional paid-in capital	8,620.4	5,636.3
Retained earnings (accumulated deficit)	(154.4)	84.3
Accumulated other comprehensive loss	(121.8)	(173.7)
Total equity	8,344.2	5,546.9
Total liabilities and equity	$ 17,237	$ 8,985.8

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, net of allowances	$ 8.8	$ 6.2
Property and equipment, net of accumulated depreciation	$ 982.7	$ 930.5
Preferred stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	5,000,000,000	5,000,000,000
Common stock, shares issued (in shares)	471,879,904	373,011,513
Common stock, shares outstanding (in shares)	471,879,904	373,011,513

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Aratana	Bayer Animal Business	Cumulative Effect, Period of Adoption, Adjustment	[2]	Common Stock	Common StockAratana	Common StockBayer Animal Business	Additional Paid-in Capital	Additional Paid-in CapitalAratana	Additional Paid-in CapitalBayer Animal Business	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit)Cumulative Effect, Period of Adoption, Adjustment	[2]	Accumulated Other Comprehensive Income (Loss)	Cash Flow Hedge Gain (Loss)	Foreign Currency Translation	Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2018							365.6
Balance at beginning of period at Dec. 31, 2018		$ 5,197.5					$ 0			$ 5,403.3			$ 16.4			$ (222.2)		$ (218.2)	$ (4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		31.5											31.5
Other comprehensive income (loss), net of tax		(28.2)														(28.2)		(30.2)	2
Separation activities	[1]	(7)								(7)
Stock compensation		2.4								2.4
Issuance of stock under employee stock plans, net (in shares)							0.1
Balance at end of period (in shares) at Mar. 31, 2019							365.7
Balance at end of period at Mar. 31, 2019		5,196.2					$ 0			5,398.7			47.9			(250.4)		(248.4)	(2)
Balance at beginning of period (in shares) at Dec. 31, 2018							365.6
Balance at beginning of period at Dec. 31, 2018		5,197.5					$ 0			5,403.3			16.4			(222.2)		(218.2)	(4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		77.4
Other comprehensive income (loss), net of tax		(30.3)
Balance at end of period (in shares) at Sep. 30, 2019							373
Balance at end of period at Sep. 30, 2019		5,487.7					$ 0			5,646.4			93.8			(252.5)		(271.9)	19.4
Balance at beginning of period (in shares) at Dec. 31, 2018							365.6
Balance at beginning of period at Dec. 31, 2018		5,197.5					$ 0			5,403.3			16.4			(222.2)		(218.2)	(4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accelerated vesting of equity awards (in shares)			0.1
Balance at end of period (in shares) at Dec. 31, 2019							373
Balance at end of period at Dec. 31, 2019		$ 5,546.9			$ (1.4)		$ 0			5,636.3			84.3	$ (1.4)		(173.7)		(198.4)	24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201613Member
Balance at beginning of period (in shares) at Mar. 31, 2019							365.7
Balance at beginning of period at Mar. 31, 2019		$ 5,196.2					$ 0			5,398.7			47.9			(250.4)		(248.4)	(2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		35.9											35.9
Other comprehensive income (loss), net of tax		35.6														35.6		35.4	0.2
Separation activities	[1]	(18.4)								(18.4)
Stock compensation		14.3								14.3
Other		1.9								1.9
Balance at end of period (in shares) at Jun. 30, 2019							365.7
Balance at end of period at Jun. 30, 2019		5,265.5					$ 0			5,396.5			83.8			(214.8)		(213)	(1.8)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		10											10
Other comprehensive income (loss), net of tax		(37.7)														(37.7)		(58.9)	21.2
Separation activities	[1]	(3)								(3)
Stock compensation		11.3								11.3
Issuance for acquisition (in shares)	[3]							7.2
Issuance for acquisition	[3]		$ 238								$ 238
Accelerated vesting of equity awards (in shares)	[3]							0.1
Accelerated vesting of equity awards	[3]		$ 3.6								$ 3.6
Balance at end of period (in shares) at Sep. 30, 2019							373
Balance at end of period at Sep. 30, 2019		5,487.7					$ 0			5,646.4			93.8			(252.5)		(271.9)	19.4
Balance at beginning of period (in shares) at Dec. 31, 2019							373
Balance at beginning of period at Dec. 31, 2019		5,546.9			(1.4)		$ 0			5,636.3			84.3	(1.4)		(173.7)		(198.4)	24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(49.1)											(49.1)
Other comprehensive income (loss), net of tax		(68.9)														(68.9)	$ (39.2)	(29.3)	(0.4)
Separation activities	[4]	15.8								15.8
Stock compensation		11.1								11.1
Issuance of stock under employee stock plans, net (in shares)							0.8
Issuance of stock under employee stock plans, net		(12.8)								(12.8)
Issuance of common stock, net of issuance costs (in shares)	[5]						25
Issuance of common stock, net of issuance costs	[5]	767.5								767.5
Issuance of tangible equity units, net of issuance costs	[5]	452.4								452.4
Balance at end of period (in shares) at Mar. 31, 2020							398.8
Balance at end of period at Mar. 31, 2020		6,661.5					$ 0			6,870.3			33.8			(242.6)	(39.2)	(227.7)	24.3
Balance at beginning of period (in shares) at Dec. 31, 2019							373
Balance at beginning of period at Dec. 31, 2019		5,546.9			$ (1.4)		$ 0			5,636.3			84.3	$ (1.4)		(173.7)		(198.4)	24.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(237.3)
Other comprehensive income (loss), net of tax		51.9
Balance at end of period (in shares) at Sep. 30, 2020							471.9
Balance at end of period at Sep. 30, 2020		8,344.2					$ 0			8,620.4			(154.4)			(121.8)	(67.4)	(76.9)	22.5
Balance at beginning of period (in shares) at Mar. 31, 2020							398.8
Balance at beginning of period at Mar. 31, 2020		6,661.5					$ 0			6,870.3			33.8			(242.6)	(39.2)	(227.7)	24.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(53.2)											(53.2)
Other comprehensive income (loss), net of tax		27.8														27.8	(20.7)	49.6	(1.1)
Separation activities	[4]	8.8								8.8
Stock compensation		8.3								8.3
Issuance of stock under employee stock plans, net (in shares)							0.1
Issuance of stock under employee stock plans, net		(1)								(1)
Other		(0.3)								(0.3)
Balance at end of period (in shares) at Jun. 30, 2020							398.9
Balance at end of period at Jun. 30, 2020		6,651.9					$ 0			6,886.1			(19.4)			(214.8)	(59.9)	(178.1)	23.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(135)											(135)
Other comprehensive income (loss), net of tax		93														93	(7.5)	101.2	(0.7)
Stock compensation		11.7								11.7
Issuance of stock under employee stock plans, net (in shares)							0.1
Issuance of stock under employee stock plans, net		(0.2)								(0.2)
Issuance for acquisition (in shares)	[6]								72.9
Issuance for acquisition	[6]			$ 1,722.8								$ 1,722.8
Balance at end of period (in shares) at Sep. 30, 2020							471.9
Balance at end of period at Sep. 30, 2020		$ 8,344.2					$ 0			$ 8,620.4			$ (154.4)			$ (121.8)	$ (67.4)	$ (76.9)	$ 22.5
[1]	See Note 17: Related Party Agreements and Transactions for further discussion.
[2]	See Note 4: Implementation of New Financial Accounting Pronouncements for further discussion.
[3]	See Note 6: Acquisitions and Divestitures for further discussion.
[4]	See Note 17: Related Party Agreements and Transactions for further discussion.
[5]	See Note 9: Equity for further discussion.
[6]	See Note 6: Acquisitions and Divestitures for further discussion.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities
Net income (loss)	$ (237.3)	$ 77.4
Adjustments to reconcile net income (loss) to cash flows from operating activities:
Depreciation and amortization	294.7	231.1
Change in deferred income taxes	(159.8)	14.9
Stock-based compensation expense	31.1	36.7
Asset impairment charges	4.7	24.7
Gain on sale of assets	(51.3)	0
Gain on divestitures (Note 6)	(169.7)	0
Changes in operating assets and liabilities, net of acquisitions	290.9	(267)
Other non-cash operating activities, net	48.6	(20)
Net Cash Provided by Operating Activities	51.9	97.8
Cash Flows from Investing Activities
Net proceeds from sale (purchases) of property and equipment	(16.2)	(49.8)
Cash paid for acquisitions, net of cash acquired (Note 6)	(5,001.3)	(32.8)
Proceeds from settlement of net investment hedges (Note 11)	32.7	0
Divestiture proceeds (Note 6)	434.7	0
Purchases of software	(147.8)	(36.2)
Other investing activities, net	(8)	(41.7)
Net Cash Used for Investing Activities	(4,705.9)	(160.5)
Cash Flows from Financing Activities
Repayments of borrowings (Note 10)	(684.2)	(115)
Proceeds from issuance of long-term debt (Note 10)	4,554.2	0
Proceeds from issuance of common stock and tangible equity units (Note 9)	1,219.9	0
Debt issuance costs	(102.5)	0
Consideration paid to Lilly in connection with the Separation (Note 1)	0	(191.6)
Other net financing transactions with Lilly	0	6.3
Other financing activities, net	(15.2)	1.7
Net Cash Provided by (Used for) Financing Activities	4,972.2	(298.6)
Effect of exchange rate changes on cash and cash equivalents	7.3	4.1
Net increase (decrease) in cash, cash equivalents and restricted cash	325.5	(357.2)
Cash, cash equivalents and restricted cash at beginning of period	345.1	677.5
Cash, cash equivalents and restricted cash at end of period	670.6	320.3
Cash, cash equivalents and restricted cash	$ 670.6	$ 320.3

Nature of Business and Organiza

Nature of Business and Organization	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Organization	Note 1. Nature of Business and Organization Nature of Business Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us or our) was formed as a wholly-owned subsidiary of Eli Lilly and Company (Lilly). Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a diverse portfolio of approximately 190 brands to veterinarians and farm animal producers in more than 90 countries. Organization Elanco Parent was formed in May 2018, as a wholly-owned subsidiary of Lilly, to serve as the ultimate parent company of substantially all of the animal health businesses of Lilly. On September 24, 2018, Elanco Parent completed an initial public offering (IPO) resulting in the issuance of 72.3 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares), which represented 19.8% of the outstanding shares, at $24 per share resulting in total net proceeds, after underwriting discounts and commissions, of $1.7 billion. In connection with the completion of the IPO, through a series of equity and other transactions, Lilly transferred to Elanco Parent the animal health businesses that form its business. In exchange, Elanco Parent has paid to Lilly approximately $4.2 billion, which included the net proceeds from the IPO, the net proceeds from the debt offering completed by Elanco Parent in August 2018 and the term loan facility entered into by Elanco Parent in September 2018 (see Note 10: Debt). These transactions are collectively referred to herein as the Separation. On February 8, 2019, Lilly announced an exchange offer whereby Lilly shareholders could exchange all or a portion of Lilly common stock for shares of Elanco common stock owned by Lilly. The disposition of Elanco shares was completed on March 11, 2019, and resulted in the full separation of Elanco along with the disposal of Lilly's entire ownership and voting interest in Elanco. On August 1, 2020, we completed the previously announced acquisition of Bayer Animal Health, for payment of $5.2 billion in cash, subject to customary post-closing adjustments, and approximately 72.9 million shares of Elanco common stock. See Note 6: Acquisitions and Divestitures for additional information.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020. Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions. The significant accounting policies set forth in Note 4 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2019 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standards that were effective January 1, 2020 as described in Note 4: Implementation of New Financial Accounting Pronouncements.

Impact of Separation

Impact of Separation	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Impact of Separation	Note 3. Impact of Separation In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA). In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions. Note 9. Equity Common Stock Offering On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs. Tangible Equity Unit (TEU) Offering On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification. The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method. The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows: Equity Component Debt Component Total Fair value per unit $ 42.80 $ 7.20 $ 50.00 Gross proceeds $ 470.8 $ 79.2 $ 550.0 Less: Issuance costs 18.4 3.1 21.5 Net proceeds $ 452.4 $ 76.1 $ 528.5 The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU. Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates: Applicable Market Value Common Stock Issued Equal to or greater than $38.40 1.3021 shares (minimum settlement rate) Less than $38.40, but greater than $32.00 $50 divided by applicable market value Less than or equal to $32.00 1.5625 (maximum settlement rate) The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.

Implementation of New Financial

Implementation of New Financial Accounting Pronouncements	9 Months Ended
	Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Implementation of New Financial Accounting Pronouncements	Note 4. Implementation of New Financial Accounting Pronouncements The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date: Standard Description Effect on the financial statements or other significant matters Accounting Standards Update 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. The following table provides a brief description of accounting standards applicable to us that have not yet been adopted: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date. We are currently evaluating the effect of this standard on our consolidated financial statements. Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Note 5. Revenue Our sales rebates are based on specific agreements and the majority relate to sales in the U.S. As of September 30, 2020 and 2019, the liability for sales rebates in the U.S. represents approximately 54% and 71%, respectively, of our total liability with the next largest country representing approximately 12% and 6%, respectively, of our total liability. The following table summarizes the activity in the sales rebates liability in the U.S.: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Beginning balance $ 122.0 $ 132.1 $ 150.4 $ 118.5 Bayer Animal Health at acquisition 20.8 — 20.8 — Reduction of revenue 86.4 75.9 212.0 222.2 Payments (78.6) (78.9) (232.6) (211.6) Ending balance $ 150.6 $ 129.1 $ 150.6 $ 129.1 Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2020 and 2019 for product shipped in previous periods were not material. Product returns in the U.S. were approximately 0.1% and less than 0.1% of net revenue for the three months ended September 30, 2020 and 2019, respectively and approximately 1.2% and 0.1% of net revenue for the nine months ended September 30, 2020 and 2019, respectively. Disaggregation of Revenue The following table summarizes our revenue disaggregated by product category: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Pet Health Disease Prevention $ 297.0 $ 207.6 $ 613.6 $ 616.9 Pet Health Therapeutics 103.3 87.6 247.1 252.4 Farm Animal Future Protein & Health 180.9 191.5 518.8 534.5 Farm Animal Ruminants & Swine 292.3 266.2 703.1 811.8 Contract Manufacturing (1) 16.1 18.4 51.0 68.4 Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0

Acquisitions and Divestitures

Acquisitions and Divestitures	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Acquisitions and Divestitures	Note 6. Acquisitions and Divestitures During 2020, we completed the acquisition of Bayer Animal Health. During 2019, we completed the acquisitions of all outstanding shares of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec). These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition. Bayer Animal Health Acquisition On August 1, 2020, we completed our previously announced acquisition of Bayer Animal Health in a cash and stock transaction. Bayer Animal Health is a provider of products intended to improve the health and well-being of pets and farm animals. The acquisition expands our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our existing product portfolio and pipeline are enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence. Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows: Cash consideration $ 5,170.1 Fair value of Elanco common stock (1) 1,723.7 Fair value of total consideration transferred (2) $ 6,893.8 (1) Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60). (2) The purchase price is preliminary and subject to working capital and customary purchase price adjustments. We recognized transaction costs related to the acquisition of Bayer Animal Health of $90.7 million and $17.4 million for the three months ended September 30, 2020 and 2019, respectively, and $212.3 million and $21.4 million for the nine months ended September 30, 2020 and 2019, respectively. These costs were associated with legal and professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations. The amount of revenues attributable to Bayer Animal Health included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2020 is $195.6 million. Based on our current operational structure, we did not record standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition. The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2020. The purchase price allocation is preliminary and subject to change, including the valuation of inventories, property and equipment, intangible assets, income taxes and goodwill, among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value. The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at August 1, 2020 Cash and cash equivalents $ 168.8 Accounts receivable 9.7 Inventories 513.9 Prepaid expenses and other current assets 57.9 Property and equipment 299.6 Intangible assets: Acquired in-process research and development 240.0 Marketed products 3,220.0 Assets held for sale 146.9 Accounts payable and accrued liabilities (172.8) Accrued retirement benefits (209.6) Other noncurrent assets and liabilities - net (707.9) Total identifiable net assets 3,566.5 Goodwill 3,327.3 Total consideration transferred $ 6,893.8 Inventories comprised of $359.6 million, $28.2 million, $126.1 million in finished products, work in process, and raw materials, respectively. The preliminary estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The preliminary estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The fair value step-up adjustment to inventories of $166.8 million is being amortized to cost of sales when the inventory is sold to customers, which is expected to be within less than one year from the acquisition date. Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment was determined to approximate net book value at the time of the acquisition based on the information currently available and pending finalization of our fair value assessment. Intangible assets relate to $240.0 million of in-process research and development (IPR&D) and $3,220.0 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the "income approach," which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of intangible assets as of September 30, 2020 is based on preliminary assumptions which are subject to change as we complete our valuation procedures. Assets held for sale include $135.0 million of marketed products rights, $7.3 million of IPR&D and $4.6 million of inventory related to the divestitures of Drontal ™, Profender ™ and other products. See the Divestitures section below for more information. Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019. Upon acquisition, the excess of projected benefit obligation over the plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated. The resulting incremental net pension expense from the acquired plans was immaterial for the three months ended September 30, 2020. The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes. The following table summarizes the changes in the carrying amount of goodwill during the period: Balance as of December 31, 2019 $ 2,989.6 Aratana measurement period adjustments 19.9 Additions related to the Bayer Animal Health acquisition 3,327.3 Foreign currency translation adjustments 97.9 Balance as of September 30, 2020 $ 6,434.7 Goodwill is reviewed for impairment at least annually and when certain impairment indicators are present. As of September 30, 2020, there were no goodwill impairment losses. Pro forma financial information (unaudited) The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenues $ 1,072.6 $ 1,111.2 $ 3,318.3 $ 3,553.7 Loss before income taxes (222.8) (144.0) (382.1) (29.2) The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco, Bayer Animal Health and Aratana. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisitions been completed on January 1, 2019, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco, Bayer Animal Health and Aratana. The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures, fair value estimates for intangibles and inventory, and interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes. Divestitures In order to secure the necessary regulatory clearances for the acquisition of Bayer Animal Health, we signed agreements to divest the rights to manufacture and commercialize certain products. The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations. Three and Nine Months Ended September 30, 2020 Gross Cash Proceeds Pre-tax Gain Osurnia™ $ 140.5 $ 93.1 Vecoxan™ 55.1 37.1 Capstar™ 95.9 25.5 Drontal and Profender™ 140.6 — Other immaterial divestitures 2.6 0.7 Total (1) $ 434.7 $ 156.4 (1) Pre-tax gain is net of transaction costs of $13.3 million. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. Elanco product divestitures In January 2020, we signed agreements to divest the worldwide rights to Osurnia and the U.S. rights to Capstar , and in February 2020, we signed an agreement to divest the worldwide rights to Vecoxan . The carrying value of the divested assets consisted of $114.1 million of marketed product rights and $7.9 million of inventory. In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures. Bayer Animal Health product divestitures To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the Drontal and Profender product families within the United Kingdom and European Economic Area as well as other IPR&D. We completed the transactions, which were accounted for as asset divestitures, on August 3, 2020. Drontal, Profender, and the IPR&D were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. A loss of $7.3 million was recorded on the sale of IPR&D as recognition of the potential income from the divestiture was constrained by revenue accounting standards. The estimated fair value of the divested assets consisted of $135.0 million of marketed product rights, $7.3 million of IPR&D, and $3.6 million of inventory. There are additional marketed and pipeline products that we are required to dispose of in order to comply with regulatory requirements. These divestitures are not expected to have a material effect on our operations, cash flows or financial position. Assets Held For Sale The related assets for the Osurnia and Capstar divestitures met the assets held for sale criteria as of December 31, 2019. No adjustments were required to record the assets at the lower of their carrying amounts or fair values less costs to sell on the consolidated balance sheet. Assets and liabilities considered held for sale in connection with the divestitures were included in the respective line items on the consolidated balance sheet as follows: December 31, 2019 Inventories $ 10.6 Other intangibles, net 61.2 Property and equipment, net 0.2 Total assets held for sale $ 72.0 Deferred taxes $ (1.4) Total liabilities held for sale $ (1.4) Other intangibles, net classified as held for sale primarily consisted of marketed products. 2019 Acquisitions Aratana Therapeutics, Inc. On July 18, 2019, we acquired Aratana, a pet therapeutics company focused on innovative therapies for dogs and cats, for stock and cash-based contingent value rights. Aratana is the creator of the canine osteoarthritis medicine, Galliprant™ , the rights to which we acquired in 2016. The acquisition enhances our presence in the areas of appetite stimulants in dogs, pain relief in dogs and cats, and treatments of other conditions in the U.S. and internationally. In connection with the acquisition, we issued approximately 7.2 million shares with a value of $238.0 million to Aratana shareholders, based on our stock price on the last trading day immediately prior to the closing date. The purchase consideration also included up to $12 million in contingent value rights, which represent the rights of Aratana shareholders to receive a contingent payment of $0.25 per share in cash upon the achievement of a specified milestone as outlined in the merger agreement. We calculated an immaterial fair value for the contingent value rights using the Monte Carlo simulation model. Contingent consideration liabilities that we previously recorded for future royalty and milestone payments in relation to the 2016 acquisition of rights to Galliprant were settled upon the closing of our acquisition of Aratana. The liabilities were valued at $84.7 million as of the acquisition date using the Monte Carlo simulation model. The resulting $7.5 million loss upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at July 18, 2019 Cash and cash equivalents $ 26.4 Inventories 10.3 Acquired in-process research and development 31.9 Marketed products (1) 36.7 Other intangible assets (1) 13.2 Other assets and liabilities - net 4.1 Total identifiable net assets 122.6 Goodwill (2) 30.7 Settlement of existing contingent consideration liabilities 84.7 Total consideration transferred $ 238.0 (1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years. (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes. The accounting for this acquisition is complete. A $19.1 million measurement period adjustment was recorded to establish a deferred tax liability for the preexisting Galliprant contingent consideration liability during the nine months ended September 30, 2020. We issued 0.1 million shares and recorded $3.6 million of stock-based compensation expense for the vesting of Aratana equity awards that was accelerated upon the closing of the acquisition during 2019. Prevtec Microbia Inc. On July 31, 2019, we acquired Prevtec in a cash transaction for approximately $60.3 million, inclusive of certain post-closing adjustments. Prevtec is a Canadian biotechnology company specializing in the development of vaccines intended to help prevent bacterial diseases in farm animals. The acquisition allows us to expand on our previous distribution arrangement for Coliprotec™ and is consistent with our efforts to explore innovative antibiotic alternatives. The purchase consideration included up to $16.3 million in additional cash consideration, contingent upon the achievement of specific sales milestones by December 31, 2021. We recorded a $4.7 million liability on the condensed consolidated balance sheet as of the acquisition date based on the fair value of the contingent consideration as calculated using the Monte Carlo simulation model. A previously existing $0.7 million receivable owed from Prevtec to Elanco Animal Health UK Limited was settled upon the closing of our acquisition of Prevtec. The resulting immaterial gain upon settlement was recorded in other - net, (income) expense in the consolidated and combined statement of operations for the year ended December 31, 2019. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at July 31, 2019 Cash and cash equivalents $ 0.9 Property and equipment 0.5 Acquired in-process research and development 2.8 Marketed products (1) 58.9 Other intangible assets 1.1 Other assets and liabilities - net (9.3) Total identifiable net assets 54.9 Goodwill (2) 10.1 Total consideration transferred $ 65.0 (1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years. (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.

Asset Impairment, Restructuring

Asset Impairment, Restructuring and Other Special Charges	9 Months Ended
	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Asset Impairment, Restructuring and Other Special Charges	Note 7. Asset Impairment, Restructuring and Other Special Charges In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis. For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions. Components of asset impairment, restructuring and other special charges are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Restructuring charges: Severance and other costs (1) (2) $ 130.2 $ 10.4 $ 131.2 $ 9.6 Facility exit costs — — 0.7 — Acquisition related charges: Transaction and integration costs (3) 131.1 46.1 318.5 99.6 Non-cash and other items: Asset impairment (4) (5) — 10.2 3.5 14.2 Asset write-down (6) 0.9 10.5 3.2 10.5 Gain on sale of fixed assets (7) — — (3.8) — Settlements and other (8) — — 3.1 Total expense $ 262.2 $ 77.2 $ 456.4 $ 133.9 (1) For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details. (2) For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. (3) Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly. (4) Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability. (5) Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization. (6) Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations. (7) Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations. (8) Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation. Following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we intend to eliminate approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in the R&D, manufacturing and quality, and back office support functions. The proposed initiative is expected to lead to total restructuring charges of approximately $190 million to $210 million through 2021, consisting primarily of severance. The following table summarizes the activity in our reserves established in connection with restructuring activities: Facility exit costs Severance Total Balance at December 31, 2018 $ 9.3 $ 35.1 $ 44.4 Charges 20.7 20.0 40.7 Reserve adjustments — (10.2) (10.2) Cash paid (2.0) (18.8) (20.8) Balance at September 30, 2019 $ 28.0 $ 26.1 $ 54.1 Balance at December 31, 2019 $ 5.4 $ 15.5 $ 20.9 Charges 0.7 131.9 132.6 Reserve adjustments — (0.8) (0.8) Cash paid (1.2) (15.0) (16.2) Balance at September 30, 2020 $ 4.9 $ 131.6 $ 136.5 These reserves are included in other current liabilities on the consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next twelve months. We believe that the reserves are adequate.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Note 8. Inventories We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method. Inventories consisted of the following: September 30, 2020 December 31, 2019 Finished products $ 797.1 $ 402.9 Work in process 664.1 603.2 Raw materials and supplies 167.0 83.9 Total 1,628.2 1,090.0 Decrease to LIFO cost (31.1) (39.3) Inventories $ 1,597.1 $ 1,050.7

Equity

Equity	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Equity	Note 3. Impact of Separation In connection with the Separation, we issued $2.0 billion aggregate principal amount of senior notes in a private placement, and we also entered into a $750.0 million senior unsecured revolving credit facility and $500.0 million senior unsecured term credit facility. In connection with the Separation, we entered into various agreements with Lilly, including a master separation agreement, a tax matters agreement and the transitional services agreement (TSA). In addition to the agreements referenced above, we entered into several other related party transactions with Lilly before and at the time of the Separation. For additional information regarding our ongoing agreements, as well as certain activities while Lilly was a related party, see Note 17: Related Party Agreements and Transactions. Note 9. Equity Common Stock Offering On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 22.7 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2.3 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25.0 million shares of our common stock for $767.5 million, after issuance costs. Tangible Equity Unit (TEU) Offering On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528.5 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification. The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the consolidated balance sheet, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method. The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows: Equity Component Debt Component Total Fair value per unit $ 42.80 $ 7.20 $ 50.00 Gross proceeds $ 470.8 $ 79.2 $ 550.0 Less: Issuance costs 18.4 3.1 21.5 Net proceeds $ 452.4 $ 76.1 $ 528.5 The senior amortizing notes have an aggregate principal amount of $79.2 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU. Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates: Applicable Market Value Common Stock Issued Equal to or greater than $38.40 1.3021 shares (minimum settlement rate) Less than $38.40, but greater than $32.00 $50 divided by applicable market value Less than or equal to $32.00 1.5625 (maximum settlement rate) The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14.3 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	Note 10. Debt Long-term debt consisted of the following: September 30, 2020 December 31, 2019 Term loan B credit facility $ 4,175.0 $ — Term credit facility — 371.4 3.912% Senior Notes due 2021 500.0 500.0 4.272% Senior Notes due 2023 750.0 750.0 4.900% Senior Notes due 2028 750.0 750.0 TEU amortizing notes 66.2 — Other obligations 0.4 0.4 Unamortized debt issuance costs (101.5) (16.8) Total debt 6,140.1 2,355.0 Less current portion of long-term debt 553.6 24.5 Total long-term debt $ 5,586.5 $ 2,330.5 Maturities on long-term debt consisted of the following: As of September 30, 2020 and for period/years ending December 31 Fourth quarter of 2020 $ 16.8 2021 567.6 2022 68.0 2023 797.5 2024 40.3 2025 39.9 Thereafter 4,711.1 Total obligations and commitments 6,241.2 Unamortized debt issuance costs and other obligations (101.1) Total debt $ 6,140.1 New Credit Facility In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we executed our previously announced borrowing of $4,275.0 million under a term loan B credit facility, of which $4,175.0 million was outstanding as of September 30, 2020. The term loan B facility bears interest at a floating rate of LIBOR plus 175 basis points over a seven Simultaneously, we entered into a revolving credit facility providing up to $750.0 million and maturing over a five We have capitalized deferred financing costs of approximately $90.2 million, consisting of legal, accounting and other fees relating to our new credit facility. Deferred financing costs are recorded as a contra-liability and presented net against long-term debt on the condensed consolidated balance sheet. Upon closing the acquisition of Bayer Animal Health on August 1, 2020, we terminated our unused commitments and incurred approximately $13.8 million in fees, which are included in other - net, (income) expense in the condensed consolidated statement of operations. Proceeds from the equity and debt activities were used to finance the cash portion of our acquisition of Bayer Animal Health and to pay related fees and expenses (see Note 6: Acquisitions and Divestitures for further discussion). Subsequent to these borrowings, we have terminated all unused commitments to our lenders. These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the term loan B facility. The lenders under the term loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility. The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter, beginning with the fiscal quarter ending September 30, 2020. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2020. The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter, beginning with the fiscal quarter ended September 30, 2020. We were in compliance with all covenants under the credit facility as of September 30, 2020. Debt Extinguishment On January 31, 2020, we repaid indebtedness outstanding under our existing term loan facility. We paid $372.4 million in cash, composed of $371.4 million of principal and $1.0 million of accrued interest, resulting in a debt extinguishment loss of $0.8 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs. On September 25, 2020, we made a repayment of principal of $100.0 million on the indebtedness outstanding under our new term loan B facility. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2.1 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statement of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs. TEU Amortizing Notes On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528.5 million was received, comprised of $452.4 million of prepaid stock purchase contracts and $76.1 million of senior amortizing notes, net of issuance costs. We paid $14.1 million representing partial payment of principal and interest on the TEU amortizing notes during the nine months ended September 30, 2020. See Note 9: Equity for further information.

Financial Instruments and Fair

Financial Instruments and Fair Value	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value	Note 11. Financial Instruments and Fair Value Financial instruments that are potentially subject to credit risk consist principally of trade receivables. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures. A large portion of our cash is held in a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value. As of September 30, 2020 and December 31, 2019, we had $21.7 million and $18.8 million, respectively, primarily related to equity method investments included in other noncurrent assets o n our condensed consolidated balance sheet. The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: Fair Value Measurements Using Financial statement line item Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair September 30, 2020 Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 10.7 $ — $ 10.7 $ — $ 10.7 Other current liabilities - foreign exchange contracts not designated as hedging instruments (7.6) — (7.6) — (7.6) Other noncurrent liabilities - contingent consideration (2.6) — — (2.6) (2.6) Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges (87.0) — (87.0) — (87.0) Long-term debt - senior notes (2,000.0) — (2,186.7) — (2,186.7) TEU amortizing note (1) (66.2) — (66.2) — (66.2) Term loan B (4,175.0) — (4,068.0) — (4,068.0) December 31, 2019 Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 0.8 $ — $ 0.8 $ — $ 0.8 Other current liabilities - foreign exchange contracts not designated as hedging instruments (1.1) — (1.1) — (1.1) Other noncurrent liabilities - contingent consideration (4.7) — — (4.7) (4.7) Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges 2.3 — 2.3 — 2.3 Long-term debt - senior notes (2,000.0) — (2,120.6) — (2,120.6) Long-term debt - term credit facility (1) (371.4) — (371.4) — (371.4) (1) We consider the carrying value to be representative of its fair value. We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. Contingent consideration liabilities as of September 30, 2020 and December 31, 2019 related to contingent consideration associated with the acquisitions of Aratana and Prevtec during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16.3 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. During the nine months ended September 30, 2020, primarily as a result of a decrease in forecasted revenues related to Coliprotec , we decreased the fair value of the contingent consideration liability associated with the Prevtec acquisition by $2.1 million, and recognized the gain in other – net, (income) expense in the condensed consolidated statement of operations. See Note 6: Acquisitions and Divestitures for further discussion. Derivative Instruments and Hedging Activities We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivatives Not Designated as Hedges We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese renminbi. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other – net, (income) expense in the condensed consolidated income statement. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2020 and December 31, 2019, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,496.9 million and $861.2 million, respectively. The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Foreign exchange forward contracts (1) $ (2.3) $ 10.1 $ 19.4 $ 8.8 (1) These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures. Derivatives Designated as Hedges In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cross-currency interest rate swap contracts $ — $ 6.2 $ 6.2 $ 18.4 Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income. The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cross-currency interest rate swap contracts $ — $ 18.5 $ 24.0 $ 23.9 Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated term loan B issuance, we executed forward-starting interest rate swaps with a $4.05 billion notional amount, which are designated as cash flow hedges and have settlement dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheet, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) will be recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., when interest payments are accrued on the term loan B). During the three and nine months ended September 30, 2020, we recorded a loss of $7.5 million (net of tax benefit of $2.2 million) and $67.4 million (net of tax benefit of $19.6 million), respectively, on the cash flow hedges in other comprehensive income (loss). Over the next 12 months we expect to reclassify $28.0 million from accumulated other comprehensive loss to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Note 12. Leases Australia Sale-Leaseback On June 26, 2020, our wholly-owned subsidiary, Elanco Australasia PTY LTD, sold land and an R&D facility located in New South Wales, Australia, for aggregate proceeds of $55.1 million, and leased the property back for an initial term of 15 years through a sale-leaseback transaction. Under the terms of the purchase and sale agreement, we determined that control of the assets was relinquished to the buyer-lessor. Therefore, we recognized a pre-tax gain on the sale of $45.6 million in other - net, (income) expense in the condensed consolidated statement of operations during the nine months ended September 30, 2020. Operating lease right-of-use assets and liabilities include the present value of $27.8 million for the associated lease payments, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes Provision for Taxes on Income Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Income tax (benefit) expense $ (74.0) $ (22.5) $ (116.6) $ 5.1 Effective tax rate 35.4 % 179.7 % 32.9 % 6.2 % Our income taxes for the nine months ended September 30, 2019 and 2020, respectively, reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return until full separation. In the jurisdictions in which we were included in a combined tax return, our income taxes were determined based on the tax matters agreement between us and Lilly. Prior to the Separation, the income tax expense included in these financial statements has been calculated using the separate return basis as if Elanco filed separate tax returns. In 2017, the U.S. enacted the Tax Cuts and Jobs Act (2017 Tax Act), which significantly revised U.S. tax law. Guidance related to the 2017 Tax Act, including Notices, Proposed Regulations, and Final Regulations, has been issued, and we expect additional guidance will be issued in 2020. This additional guidance could materially impact our assumptions and estimates used to record our U.S. federal and state income tax expense resulting from the 2017 Tax Act. We are included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. During the fourth quarter of 2019, the IRS began its examination of tax years 2016 - 2018. Because the examination is still in the early stages of information gathering, the resolution of the audit will likely extend beyond the next 12 months. For the three and nine months ended September 30, 2020, we recognized $74.0 million and $116.6 million, respectively, of income tax benefit. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates. For the three and nine months ended September 30, 2019, we recognized a tax benefit of $22.5 million and incurred $5.1 million of income tax expense, respectively. For the three and nine months ended September 30, 2019, our effective tax rate differs from the statutory income tax rate primarily due to a discrete tax benefit from the resolution of a Brazil tax audit in addition to the impact of lower pre-tax earnings largely due to restructuring charges. Tax reserves had been established in the 2015 acquisition of Novartis Animal Health (Novartis) and were partially covered by an indemnity. The favorable resolution of the Brazil tax audit resulted in an income tax benefit of approximately $14 million in the third quarter of 2019.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14. Commitments and Contingencies Legal Matters On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between January 10, 2020 and May 6, 2020. On September 3, 2020, the Court appointed a lead plaintiff. The deadline for the lead plaintiff to file an amended complaint is November 9, 2020. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted. On October 16, 2020, a shareholder class action lawsuit captioned Safron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3/ASR dated January 21, 2020 and accompanying prospectus on Form 424B5 issued in connection with Elanco’s secondary public offering that closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities pursuant to the secondary public offering. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

Geographic Information

Geographic Information	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Geographic Information	Note 15. Geographic Information We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant cost/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. We are currently in the process of reviewing our operating segments as a result of potential changes to our operational structure due to the acquisition of Bayer Animal Health. Our products include Rumensin™ , Optaflexx™ , Denagard™ , Tylan™ , Maxiban™, Baycox™, Cydectin™ and other products for livestock and poultry, as well as Trifexis™ , Intercepto r ™ , Comfortis™ , Galliprant, Seresto™, Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family) and other products for pets. We have a single customer that accounted for 11.7% and 15.9% of revenue for the three months ended September 30, 2020 and 2019, respectively, and for 11.9% and 13.4% of revenue for the nine months ended September 30, 2020 and 2019, respectively. The product sales resulted in accounts receivable with this customer of $78.1 million and $90.5 million as of September 30, 2020 and December 31, 2019, respectively. We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates. Selected geographic area information was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenue—to unaffiliated customers (1) United States $ 421.5 $ 388.2 $ 969.5 $ 1,167.1 International 468.1 383.1 1,164.1 1,116.9 Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0 September 30, 2020 December 31, 2019 Long-lived assets (2) United States $ 942.6 $ 709.8 Germany 243.7 39.7 United Kingdom 206.3 192.6 Other foreign countries 273.1 205.0 Long-lived assets $ 1,665.7 $ 1,147.1 (1) Revenue is attributed to the countries based on the location of the customer. (2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Note 16. Earnings Per Share Basic Earnings Per Share We compute basic earnings (loss) per share by dividing net earnings (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. For the three and nine months ended September 30, 2020, the weighted average number of common shares outstanding used to calculate basic earnings per share includes the impact of approximately 72.9 million shares of common stock issued to Bayer and its subsidiaries for the Bayer Animal Health acquisition. In addition, basic earnings per share reflects the impacts of 25.0 million shares and 14.3 million shares, respectively, issued in connection with our common stock and TEU issuances in the first quarter of 2020. See Note 6: Acquisitions and Divestitures and Note 9: Equity for further discussion. Diluted Earnings Per Share Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts. Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Weighted average diluted shares outstanding included common stock equivalents of 1.5 million and 1.0 million for the three and nine months ended September 30, 2019, respectively. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. During the three and nine months ended September 30, 2020, we reported a net loss. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share.

Related Party Agreements and Tr

Related Party Agreements and Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Agreements and Transactions	Note 17. Related Party Agreements and Transactions Elanco Shares Held by Bayer On August 1, 2020, we completed the acquisition of Bayer Animal Health, which included cash and Elanco stock consideration. Pursuant to the share and asset purchase agreement, Bayer has the right to sell such shares on or after November 1, 2020 through multiple registered offerings. Upon Bayer's written request, Elanco is obligated to use commercially reasonable efforts to file a shelf registration statement covering the resale by Bayer of its Elanco common stock. As of September 30, 2020, Bayer owns 72.9 million shares, or 15.5% of our outstanding common stock. Transactions with Bayer Subsequent to the Acquisition of Bayer Animal Health There were various transactions between us and Bayer during the period after the acquisition of Bayer Animal Health. The total net payable due to Bayer at September 30, 2020 was $9.8 million related to these transactions. We also have $60.0 million associated with lease agreements with Bayer recorded on our condensed consolidated balance sheet as of September 30, 2020. Further details regarding our ongoing relationship with Bayer are included below. Transitional Services Agreements (TSA) and Reverse TSAs To ensure business continuity after the acquisition of the Bayer Animal Health business, we entered into certain TSAs and reverse TSAs with Bayer. Under the TSAs, Bayer will provide us certain specified R&D services and back office support on a transitional basis, including among other things, logistical services, commercial operations support, and information systems. We will pay Bayer mutually agreed-upon fees for services provided under the TSAs, a majority of which are based on fixed hourly rates, and subject to a contractually agreed mark-up. We have recorded approximately $2.7 million of expense for the three and nine months ended September 30, 2020 related to these agreements. The reverse TSAs are primarily comprised of contracts whereby we have agreed to provide Bayer certain R&D services on a transitional basis. During the three and nine months ended September 30, 2020, reverse TSA activity was immaterial. Leases We lease certain facilities and fleet vehicles from Bayer. Our operating lease right-of-use assets and liabilities include the present value of $60.0 million for the lease payments related to these leases, which are presented in other noncurrent assets and other noncurrent liabilities and other current liabilities on the condensed consolidated balance sheet. Local Country Asset Purchases For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer is to provide a refund for payment amounts duplicated in these regions. As of September 30, 2020, the local payment has not yet been made in China due to certain regulatory delays. Thus, as of September 30, 2020, we had a receivable from and payable to Bayer of $233.6 million and $233.6 million, respectively, recorded on a net basis on the condensed consolidated balance sheet. Other Activities We also entered into various other agreements with Bayer, including certain supply agreements and contract manufacturing and toll manufacturing agreements. These contracts are for activities in the normal course of business and are required to maintain and establish business relationships on a long-term basis. In connection with the acquisition, we have an obligation to reimburse Bayer for certain costs they incurred on our behalf. Accordingly, we have recorded approximately $20.4 million in other current liabilities on the condensed consolidated balance sheet as of September 30, 2020 and within asset impairment, restructuring and other special charges in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020 for amounts owed to Bayer. Transactions with Lilly Subsequent to Separation and Related to the Separation Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows: September 30, 2020 December 31, 2019 TSA $ 1.1 $ 10.5 Other activities (1.7) (15.8) Local country asset purchases (10.7) (11.1) Total payable to Lilly $ (11.3) $ (16.4) As described in Note 1, we completed an IPO in September 2018 and Lilly fully divested all ownership of Elanco in March 2019. In connection with the Separation, we entered into various agreements with Lilly related to the form of our separation and certain ongoing activities that will continue for a period of time. These included, among others, a master separation agreement (MSA), a TSA and a tax matters agreement. In addition, there was a portion of our operations for which the legal transfer of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. TSA Historically, Lilly has provided us significant shared services and resources related to corporate functions such as executive oversight, treasury, legal, finance, human resources, tax, internal audit, financial reporting, information technology and investor relations, which we refer to collectively as the "Lilly Services." Under the terms of the TSA, we are able to use Lilly Services for a fixed term established on a service-by-service basis. We pay Lilly mutually agreed-upon fees for the Lilly Services provided under the TSA, which are based on Lilly's cost (including third-party costs) of providing the Lilly Services through March 31, 2021, and subject to a mark-up of 7% thereafter, with additional inflation-based escalation beginning January 1, 2022. The fees under the TSA became payable for all periods beginning after October 1, 2018. Separation Activities Subsequent to our IPO, there continue to be transactions between us and Lilly related primarily to the completion of the local country asset purchases and finalization of assets and liabilities associated with the legal separation from Lilly, combined income tax returns and the impact of the tax matters agreement, historical Lilly retirement benefits, and centralized cash management. The most significant of these activities includes the finalization of the local country valuation of business and the resulting impact on deferred tax assets and the impact of combined tax returns. Other Activities We continue to share certain services and back office functions with Lilly, which in certain instances result in Lilly paying costs for Elanco (e.g., utilities, local country operating costs, etc.) that are then passed through to Elanco for reimbursement. These amounts are included in cash flows from operating activities in our consolidated statements of cash flows. In addition, we operate through a single treasury settlement process and prior to the local country asset purchases (as described below) continued to transact through Lilly's processes in certain instances. As a result of these activities, there were certain amounts of financing that occurred between Lilly and Elanco during the nine months ended September 30, 2019 and 2020. These amounts are included in cash flows from financing activities in our condensed consolidated statements of cash flows. Local Country Asset Purchases The legal transfer of certain of our net assets did not occur prior to the Separation due to certain regulatory requirements in each of these countries. The related assets, liabilities, and results of operations have been reported in our condensed consolidated financial statements, as we are responsible for the business activities conducted by Lilly on our behalf and are subject to the risks and entitled to the benefits generated by these operations and assets under the terms of the MSA. We held restricted cash, and the associated payable to Lilly, at the date of Separation to fund the acquisition of these assets. As of September 30, 2020, the majority of these assets have been legally acquired and the remainder are expected to be purchased during 2020. Restricted cash and Payable to Lilly of $10.7 million are recorded on the condensed consolidated balance sheet for the remainder of the assets expected to be purchased by the end of 2020. Transactions with Lilly Prior to Full Separation Prior to the IPO, we did not operate as a standalone business and had various relationships with Lilly whereby Lilly provided services to us. The impact on our historical combined financial statements includes the following: Stock-based Compensation

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The accounts of all wholly owned and controlled subsidiaries are included in the condensed consolidated financial statements and all intercompany balances and transactions have been eliminated.
Reclassifications	Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with current presentation.
Consolidation	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2019 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020.
Income Tax	Our income taxes in 2019 and thereafter reflect the results on a stand-alone basis independent of Lilly, except for the period during which we were included in a combined tax return with Lilly until full separation. The income tax amounts in the financial statements have been calculated based on a separate return methodology and presented as if our operations were separate taxpayers in the respective jurisdictions. We file income tax returns in the U.S. federal jurisdiction and various state, local and non-U.S. jurisdictions.
Implementation of New Financial Accounting Pronouncements	The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date: Standard Description Effect on the financial statements or other significant matters Accounting Standards Update 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. The following table provides a brief description of accounting standards applicable to us that have not yet been adopted: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date. We are currently evaluating the effect of this standard on our consolidated financial statements. Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.

Implementation of New Financi_2

Implementation of New Financial Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Description of Accounting Standards Adopted and Not Yet Adopted	The following table provides a brief description of accounting standards that were effective January 1, 2020 and were adopted on that date: Standard Description Effect on the financial statements or other significant matters Accounting Standards Update 2016-13 Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This standard modifies the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables. We adopted the standard using the modified retrospective approach. The impact of adoption included the first-time recognition of expected credit losses (i.e., bad debt expense) on current receivables that are not past due, which resulted in a decrease in retained earnings of $1.4 million. Recognition of this allowance and other impacts of adoption were not material to the consolidated financial statements. Accounting Standards Update 2018-15, Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract This guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. We implemented the guidance on a prospective basis. The adoption did not have a significant impact on the consolidated financial statements. The following table provides a brief description of accounting standards applicable to us that have not yet been adopted: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2019-12, Simplifying the Accounting for Income Taxes The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This standard is effective January 1, 2021, with early adoption permitted. We intend to adopt this standard on that date. We are currently evaluating the effect of this standard on our consolidated financial statements. Accounting Standards Update 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting This update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. This standard was effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis. We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts, but do not expect that this update will have a material impact on our consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Summary of Activity in Sales Rebates and Discounts Liability	The following table summarizes the activity in the sales rebates liability in the U.S.: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Beginning balance $ 122.0 $ 132.1 $ 150.4 $ 118.5 Bayer Animal Health at acquisition 20.8 — 20.8 — Reduction of revenue 86.4 75.9 212.0 222.2 Payments (78.6) (78.9) (232.6) (211.6) Ending balance $ 150.6 $ 129.1 $ 150.6 $ 129.1
Disaggregation of Revenue	The following table summarizes our revenue disaggregated by product category: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Pet Health Disease Prevention $ 297.0 $ 207.6 $ 613.6 $ 616.9 Pet Health Therapeutics 103.3 87.6 247.1 252.4 Farm Animal Future Protein & Health 180.9 191.5 518.8 534.5 Farm Animal Ruminants & Swine 292.3 266.2 703.1 811.8 Contract Manufacturing (1) 16.1 18.4 51.0 68.4 Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Purchase Consideration	Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows: Cash consideration $ 5,170.1 Fair value of Elanco common stock (1) 1,723.7 Fair value of total consideration transferred (2) $ 6,893.8 (1) Represents the acquisition date fair value of 72.9 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at August 1, 2020 Cash and cash equivalents $ 168.8 Accounts receivable 9.7 Inventories 513.9 Prepaid expenses and other current assets 57.9 Property and equipment 299.6 Intangible assets: Acquired in-process research and development 240.0 Marketed products 3,220.0 Assets held for sale 146.9 Accounts payable and accrued liabilities (172.8) Accrued retirement benefits (209.6) Other noncurrent assets and liabilities - net (707.9) Total identifiable net assets 3,566.5 Goodwill 3,327.3 Total consideration transferred $ 6,893.8 The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at July 18, 2019 Cash and cash equivalents $ 26.4 Inventories 10.3 Acquired in-process research and development 31.9 Marketed products (1) 36.7 Other intangible assets (1) 13.2 Other assets and liabilities - net 4.1 Total identifiable net assets 122.6 Goodwill (2) 30.7 Settlement of existing contingent consideration liabilities 84.7 Total consideration transferred $ 238.0 (1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of approximately 12.5 years. (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Aratana with our legacy business. The majority of goodwill associated with this acquisition is not deductible for tax purposes. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at July 31, 2019 Cash and cash equivalents $ 0.9 Property and equipment 0.5 Acquired in-process research and development 2.8 Marketed products (1) 58.9 Other intangible assets 1.1 Other assets and liabilities - net (9.3) Total identifiable net assets 54.9 Goodwill (2) 10.1 Total consideration transferred $ 65.0 (1) These intangible assets, which are being amortized on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 10 years. (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies from combining the operations of Prevtec with our legacy business and future unidentified projects and products. The goodwill associated with this acquisition is not deductible for tax purposes.
Schedule of Goodwill	The following table summarizes the changes in the carrying amount of goodwill during the period: Balance as of December 31, 2019 $ 2,989.6 Aratana measurement period adjustments 19.9 Additions related to the Bayer Animal Health acquisition 3,327.3 Foreign currency translation adjustments 97.9 Balance as of September 30, 2020 $ 6,434.7
Pro Forma Information	The following table presents the estimated unaudited pro forma combined results of Elanco, Bayer Animal Health and Aratana for the three and nine months ended September 30, 2020 and 2019 as if the acquisitions had occurred on January 1, 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenues $ 1,072.6 $ 1,111.2 $ 3,318.3 $ 3,553.7 Loss before income taxes (222.8) (144.0) (382.1) (29.2)
Divestitures Activities	The following table summarizes the financial impact of the material divestitures completed during the third quarter of 2020, the pre-tax gains and losses on which are included in other - net, (income) expense in the condensed consolidated statement of operations. Three and Nine Months Ended September 30, 2020 Gross Cash Proceeds Pre-tax Gain Osurnia™ $ 140.5 $ 93.1 Vecoxan™ 55.1 37.1 Capstar™ 95.9 25.5 Drontal and Profender™ 140.6 — Other immaterial divestitures 2.6 0.7 Total (1) $ 434.7 $ 156.4 (1) Pre-tax gain is net of transaction costs of $13.3 million. December 31, 2019 Inventories $ 10.6 Other intangibles, net 61.2 Property and equipment, net 0.2 Total assets held for sale $ 72.0 Deferred taxes $ (1.4) Total liabilities held for sale $ (1.4)

Asset Impairment, Restructuri_2

Asset Impairment, Restructuring and Other Special Charges (Tables)	9 Months Ended
	Sep. 30, 2020
Restructuring and Related Activities [Abstract]
Total Charges Related to Asset Impairment, Restructuring and Other Special Charges	Components of asset impairment, restructuring and other special charges are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Restructuring charges: Severance and other costs (1) (2) $ 130.2 $ 10.4 $ 131.2 $ 9.6 Facility exit costs — — 0.7 — Acquisition related charges: Transaction and integration costs (3) 131.1 46.1 318.5 99.6 Non-cash and other items: Asset impairment (4) (5) — 10.2 3.5 14.2 Asset write-down (6) 0.9 10.5 3.2 10.5 Gain on sale of fixed assets (7) — — (3.8) — Settlements and other (8) — — 3.1 Total expense $ 262.2 $ 77.2 $ 456.4 $ 133.9 (1) For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program initiated following the acquisition of Bayer Animal Health. See below for further details. (2) For the three and nine months ended September 30, 2019, these charges primarily related to a restructuring program initiated in 2019 to reduce costs and support margin expansion by eliminating certain positions across multiple locations and functions, including exiting research and development (R&D) operations in Prince Edward Island, Canada, ceasing certain manufacturing operations in Wusi, China, and streamlining operations in Speke, England. (3) Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisition of Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as stand-up costs related to the implementation of new systems, programs, and processes due to the Separation from Lilly. (4) Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an in-process research and development asset resulting from a reassessment of geographic viability. (5) Asset impairment charges for the three and nine months ended September 30, 2019 related to an adjustment to fair value of intangible assets that were subject to product rationalization. (6) Asset write-down expenses for the three and nine months ended September 30, 2020 and 2019 resulted from adjustments recorded to write assets classified as held and used down to their current fair value. Included are charges related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations. (7) Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada, which was written down during the three months ended September 30, 2019 as part of the announced 2019 program to streamline operations. (8) Charge primarily relates to a non-recurring litigation settlement for a matter that originated prior to the Separation.
Summary of Activity in Reserves	The following table summarizes the activity in our reserves established in connection with restructuring activities: Facility exit costs Severance Total Balance at December 31, 2018 $ 9.3 $ 35.1 $ 44.4 Charges 20.7 20.0 40.7 Reserve adjustments — (10.2) (10.2) Cash paid (2.0) (18.8) (20.8) Balance at September 30, 2019 $ 28.0 $ 26.1 $ 54.1 Balance at December 31, 2019 $ 5.4 $ 15.5 $ 20.9 Charges 0.7 131.9 132.6 Reserve adjustments — (0.8) (0.8) Cash paid (1.2) (15.0) (16.2) Balance at September 30, 2020 $ 4.9 $ 131.6 $ 136.5

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: September 30, 2020 December 31, 2019 Finished products $ 797.1 $ 402.9 Work in process 664.1 603.2 Raw materials and supplies 167.0 83.9 Total 1,628.2 1,090.0 Decrease to LIFO cost (31.1) (39.3) Inventories $ 1,597.1 $ 1,050.7

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Stockholders Equity	The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows: Equity Component Debt Component Total Fair value per unit $ 42.80 $ 7.20 $ 50.00 Gross proceeds $ 470.8 $ 79.2 $ 550.0 Less: Issuance costs 18.4 3.1 21.5 Net proceeds $ 452.4 $ 76.1 $ 528.5 Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates: Applicable Market Value Common Stock Issued Equal to or greater than $38.40 1.3021 shares (minimum settlement rate) Less than $38.40, but greater than $32.00 $50 divided by applicable market value Less than or equal to $32.00 1.5625 (maximum settlement rate)

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consisted of the following: September 30, 2020 December 31, 2019 Term loan B credit facility $ 4,175.0 $ — Term credit facility — 371.4 3.912% Senior Notes due 2021 500.0 500.0 4.272% Senior Notes due 2023 750.0 750.0 4.900% Senior Notes due 2028 750.0 750.0 TEU amortizing notes 66.2 — Other obligations 0.4 0.4 Unamortized debt issuance costs (101.5) (16.8) Total debt 6,140.1 2,355.0 Less current portion of long-term debt 553.6 24.5 Total long-term debt $ 5,586.5 $ 2,330.5
Schedule of Maturities of Long-term Debt	Maturities on long-term debt consisted of the following: As of September 30, 2020 and for period/years ending December 31 Fourth quarter of 2020 $ 16.8 2021 567.6 2022 68.0 2023 797.5 2024 40.3 2025 39.9 Thereafter 4,711.1 Total obligations and commitments 6,241.2 Unamortized debt issuance costs and other obligations (101.1) Total debt $ 6,140.1

Financial Instruments and Fai_2

Financial Instruments and Fair Value (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Fair Value Information	The following table summarizes the fair value information at September 30, 2020 and December 31, 2019 for foreign exchange contract assets (liabilities), contingent consideration liabilities, net investment hedge assets (liabilities) and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: Fair Value Measurements Using Financial statement line item Carrying Quoted Prices in Active Markets for Identical Assets Significant Significant Fair September 30, 2020 Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 10.7 $ — $ 10.7 $ — $ 10.7 Other current liabilities - foreign exchange contracts not designated as hedging instruments (7.6) — (7.6) — (7.6) Other noncurrent liabilities - contingent consideration (2.6) — — (2.6) (2.6) Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges (87.0) — (87.0) — (87.0) Long-term debt - senior notes (2,000.0) — (2,186.7) — (2,186.7) TEU amortizing note (1) (66.2) — (66.2) — (66.2) Term loan B (4,175.0) — (4,068.0) — (4,068.0) December 31, 2019 Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 0.8 $ — $ 0.8 $ — $ 0.8 Other current liabilities - foreign exchange contracts not designated as hedging instruments (1.1) — (1.1) — (1.1) Other noncurrent liabilities - contingent consideration (4.7) — — (4.7) (4.7) Other noncurrent assets - cross currency interest rate contracts designated as net investment hedges 2.3 — 2.3 — 2.3 Long-term debt - senior notes (2,000.0) — (2,120.6) — (2,120.6) Long-term debt - term credit facility (1) (371.4) — (371.4) — (371.4)
Net Gain/Loss on Derivative Instruments	The amount of net gain/(loss) on derivative instruments not designated as hedging instruments, recorded in other - net, (income) expense are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Foreign exchange forward contracts (1) $ (2.3) $ 10.1 $ 19.4 $ 8.8 (1) These amounts were substantially offset in other – net, (income) expense by the effect of changing exchange rates on the underlying foreign currency exposures. Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cross-currency interest rate swap contracts $ — $ 6.2 $ 6.2 $ 18.4 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cross-currency interest rate swap contracts $ — $ 18.5 $ 24.0 $ 23.9

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Provision for Taxes on Income	Provision for Taxes on Income Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Income tax (benefit) expense $ (74.0) $ (22.5) $ (116.6) $ 5.1 Effective tax rate 35.4 % 179.7 % 32.9 % 6.2 %

Geographic Information (Tables)

Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Revenue by Selected Geographic Area Information	Selected geographic area information was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Revenue—to unaffiliated customers (1) United States $ 421.5 $ 388.2 $ 969.5 $ 1,167.1 International 468.1 383.1 1,164.1 1,116.9 Revenue $ 889.6 $ 771.3 $ 2,133.6 $ 2,284.0
Long-lived Assets by Selected Geographic Area Information	September 30, 2020 December 31, 2019 Long-lived assets (2) United States $ 942.6 $ 709.8 Germany 243.7 39.7 United Kingdom 206.3 192.6 Other foreign countries 273.1 205.0 Long-lived assets $ 1,665.7 $ 1,147.1 (1) Revenue is attributed to the countries based on the location of the customer. (2) Long-lived assets consist of property and equipment, net, and certain noncurrent assets, including right-of-use assets.

Related Party Agreements and _2

Related Party Agreements and Transactions (Tables)	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Amounts Due From/(Due To) Lilly and Allocations of Services	Amounts due from/(due to) Lilly in connection with the Separation and agreed upon services were as follows: September 30, 2020 December 31, 2019 TSA $ 1.1 $ 10.5 Other activities (1.7) (15.8) Local country asset purchases (10.7) (11.1) Total payable to Lilly $ (11.3) $ (16.4)

Nature of Business and Organi_2

Nature of Business and Organization (Details) $ / shares in Units, shares in Millions, $ in Millions	Aug. 01, 2020USD ($)shares	Jan. 23, 2020USD ($)shares	Sep. 24, 2018USD ($)$ / sharesshares	Sep. 30, 2020brandcountryshares	Sep. 30, 2020brandcountryshares
Subsidiary, Sale of Stock [Line Items]
Number of brands in diverse portfolio | brand				190	190
Number of countries in which entity operates (more than) | country				90	90
Number of shares issued (in shares) | shares		25
Total net proceeds, after underwriting discounts and commissions		$ 767.5
Bayer Animal Business
Subsidiary, Sale of Stock [Line Items]
Cash paid in acquisition	$ 5,170.1
Shares issued to previous shareholders upon closing (in shares) | shares	72.9			72.9	72.9
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares issued (in shares) | shares			72.3
Percentage of total outstanding shares			19.80%
Price per share (usd per share) | $ / shares			$ 24
Total net proceeds, after underwriting discounts and commissions			$ 1,700
Payments made to date			$ 4,200

Impact of Separation (Details)

Impact of Separation (Details) - USD ($)	Aug. 01, 2020	Sep. 24, 2018
Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 2,000,000,000
Credit Facility | Senior Unsecured Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 750,000,000	750,000,000
Credit Facility | Senior Unsecured Term Credit Facility
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 500,000,000

Implementation of New Financi_3

Implementation of New Financial Accounting Pronouncements (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Decrease due to adoption	$ (84.3)	$ 154.4
Cumulative Effect, Period of Adoption, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease due to adoption	$ 1.4

Revenue - Narrative (Details)

Revenue - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Geographic Concentration Risk | Contract With Customer Liability | United States
Concentration Risk [Line Items]
Concentration risk (less than 0.1%)			54.00%	71.00%
Geographic Concentration Risk | Contract With Customer Liability | Next Largest Country
Concentration Risk [Line Items]
Concentration risk (less than 0.1%)			12.00%	6.00%
Product Return Concentration Risk | Net Revenue
Concentration Risk [Line Items]
Concentration risk (less than 0.1%)	0.10%	0.10%	1.20%	0.10%

Revenue - Summary of Activity i

Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Change In Contract With Customer, Liability [Roll Forward]
Beginning balance	$ 122	$ 132.1	$ 150.4	$ 118.5
Bayer Animal Health at acquisition	20.8	0	20.8	0
Reduction of revenue	86.4	75.9	212	222.2
Payments	(78.6)	(78.9)	(232.6)	(211.6)
Ending balance	$ 150.6	$ 129.1	$ 150.6	$ 129.1

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 889.6	$ 771.3	$ 2,133.6	$ 2,284
Pet Health Disease Prevention
Disaggregation of Revenue [Line Items]
Revenue	297	207.6	613.6	616.9
Pet Health Therapeutics
Disaggregation of Revenue [Line Items]
Revenue	103.3	87.6	247.1	252.4
Farm Animal Future Protein & Health
Disaggregation of Revenue [Line Items]
Revenue	180.9	191.5	518.8	534.5
Farm Animal Ruminants & Swine
Disaggregation of Revenue [Line Items]
Revenue	292.3	266.2	703.1	811.8
Contract Manufacturing
Disaggregation of Revenue [Line Items]
Revenue	$ 16.1	$ 18.4	$ 51	$ 68.4

Acquisitions and Divestitures -

Acquisitions and Divestitures - Purchase Consideration (Details) - Bayer Animal Business - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Aug. 01, 2020	Sep. 30, 2020	Sep. 30, 2020
Business Acquisition [Line Items]
Cash consideration	$ 5,170.1
Fair value of Elanco common stock	1,723.7
Fair value of total consideration transferred (2)	$ 6,893.8
Shares issued to previous shareholders upon closing (in shares)	72.9	72.9	72.9
Common stock price (in dollars per share)	$ 23.64
Fair value used in estimate	$ 2,300
Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration	20 days
Symmetrical collar (as a percent)	7.50%
Volume weighted average price for thirty trading days (usd per share)	$ 33.60

Acquisitions and Divestitures_2

Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Aug. 01, 2020	Jul. 31, 2019	Jul. 18, 2019	Sep. 30, 2020	Dec. 31, 2019
Intangible assets:
Goodwill				$ 6,434.7	$ 2,989.6
Bayer Animal Business
Business Acquisition [Line Items]
Cash and cash equivalents	$ 168.8
Accounts receivable	9.7
Inventories	513.9
Prepaid expenses and other current assets	57.9
Property and equipment	299.6
Intangible assets:
Assets held for sale	146.9
Accounts payable and accrued liabilities	(172.8)
Accrued retirement benefits	(209.6)
Other noncurrent assets and liabilities - net	(707.9)
Total identifiable net assets	3,566.5
Goodwill	3,327.3
Total consideration transferred	$ 6,893.8
Average useful life	12 years
Bayer Animal Business | Marketed products
Intangible assets:
Finite lived intangible assets	$ 3,220
Bayer Animal Business | In-Process Research and Development
Intangible assets:
Acquired in-process research and development	$ 240
Aratana
Business Acquisition [Line Items]
Cash and cash equivalents			$ 26.4
Inventories			10.3
Intangible assets:
Other assets and liabilities - net			4.1
Total identifiable net assets			122.6
Goodwill			30.7
Settlement of existing contingent consideration liabilities			84.7
Total consideration transferred			$ 238
Average useful life			12 years 6 months
Aratana | Marketed products
Intangible assets:
Finite lived intangible assets			$ 36.7
Aratana | Other intangible assets
Intangible assets:
Finite lived intangible assets			13.2
Aratana | In-Process Research and Development
Intangible assets:
Acquired in-process research and development			$ 31.9
Prevtec
Business Acquisition [Line Items]
Cash and cash equivalents		$ 0.9
Property and equipment		0.5
Intangible assets:
Other assets and liabilities - net		(9.3)
Total identifiable net assets		54.9
Goodwill		10.1
Total consideration transferred		$ 65
Average useful life		10 years
Prevtec | Marketed products
Intangible assets:
Finite lived intangible assets		$ 58.9
Prevtec | Other intangible assets
Intangible assets:
Finite lived intangible assets		1.1
Prevtec | In-Process Research and Development
Intangible assets:
Acquired in-process research and development		$ 2.8

Acquisitions and Divestitures_3

Acquisitions and Divestitures - Narrative (Details) - USD ($) $ / shares in Units, shares in Millions	Aug. 03, 2020	Aug. 01, 2020	Jul. 31, 2019	Jul. 18, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jul. 31, 2020
Business Acquisition [Line Items]
Revenue					$ 889,600,000	$ 771,300,000	$ 2,133,600,000	$ 2,284,000,000
Goodwill impairment							0
Gain (loss) on disposition of business							169,700,000	0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Business Acquisition [Line Items]
Gain (loss) on disposition of business					156,400,000		156,400,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan | Inventories
Business Acquisition [Line Items]
Divested assets, fair value										$ 7,900,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Worldwide Rights to Osurnia, U.S. Rights to Capstar and Worldwide Rights to Vecoxan | Marketed products
Business Acquisition [Line Items]
Divested assets, fair value										$ 114,100,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal
Business Acquisition [Line Items]
Gain (loss) on disposition of business	$ 0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | Inventories
Business Acquisition [Line Items]
Assets held for sale		$ 4,600,000
Divested assets, fair value	3,600,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | Marketed products
Business Acquisition [Line Items]
Assets held for sale		135,000,000
Divested assets, fair value	135,000,000
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | In-Process Research and Development
Business Acquisition [Line Items]
Assets held for sale		7,300,000
Divested assets, fair value	7,300,000
Gain (loss) on disposition of business	$ 7,300,000
Bayer Animal Business
Business Acquisition [Line Items]
Transaction costs					90,700,000	$ 17,400,000	212,300,000	$ 21,400,000
Revenue					$ 195,600,000		$ 195,600,000
Inventories		513,900,000
Business combination, inventories, step-up fair value adjustment		$ 166,800,000
Average useful life		12 years
Assets held for sale		$ 146,900,000
Shares issued to previous shareholders upon closing (in shares)		72.9			72.9		72.9
Value of shares issued as consideration		$ 1,723,700,000
Consideration paid for acquisition		6,893,800,000
Bayer Animal Business | In-Process Research and Development
Business Acquisition [Line Items]
Acquired in-process research and development		240,000,000
Bayer Animal Business | Marketed products
Business Acquisition [Line Items]
Finite lived intangible assets		3,220,000,000
Bayer Animal Business | Finished Products
Business Acquisition [Line Items]
Inventories		359,600,000
Bayer Animal Business | in Process
Business Acquisition [Line Items]
Inventories		28,200,000
Bayer Animal Business | Raw Materials
Business Acquisition [Line Items]
Inventories		$ 126,100,000
Aratana
Business Acquisition [Line Items]
Inventories				$ 10,300,000
Average useful life				12 years 6 months
Shares issued to previous shareholders upon closing (in shares)				7.2
Value of shares issued as consideration				$ 238,000,000
Contingent value rights included in purchase consideration				$ 12,000,000
Contingent payment (usd per share)				$ 0.25
Measurement period adjustment							$ 19,100,000
Accelerated vesting of equity awards (in shares)									0.1
Accelerated stock based compensation expense									$ 3,600,000
Aratana | In-Process Research and Development
Business Acquisition [Line Items]
Acquired in-process research and development				$ 31,900,000
Aratana | Marketed products
Business Acquisition [Line Items]
Finite lived intangible assets				36,700,000
Galliprant
Business Acquisition [Line Items]
Contingent consideration liability				$ 84,700,000
Loss upon settlement of contingent consideration liability									$ 7,500,000
Prevtec
Business Acquisition [Line Items]
Average useful life			10 years
Contingent value rights included in purchase consideration			$ 16,300,000
Contingent consideration liability			4,700,000
Loss upon settlement of contingent consideration liability							$ 2,100,000
Consideration paid for acquisition			60,300,000
Settlement of accounts receivable			700,000
Prevtec | In-Process Research and Development
Business Acquisition [Line Items]
Acquired in-process research and development			2,800,000
Prevtec | Marketed products
Business Acquisition [Line Items]
Finite lived intangible assets			$ 58,900,000

Acquisitions and Divestitures_4

Acquisitions and Divestitures - Carrying Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,989.6
Aratana measurement period adjustments	19.9
Additions related to the Bayer Animal Health acquisition	3,327.3
Foreign currency translation adjustments	97.9
Goodwill, ending balance	$ 6,434.7

Acquisitions and Divestitures_5

Acquisitions and Divestitures - Pro Forma Information (Details) - Bayer Animal Business - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Revenues	$ 1,072.6	$ 1,111.2	$ 3,318.3	$ 3,553.7
Loss before income taxes	$ (222.8)	$ (144)	$ (382.1)	$ (29.2)

Acquisitions and Divestitures_6

Acquisitions and Divestitures - Divestitures (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds		$ 434.7	$ 0
Pre-tax Gain		169.7	$ 0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	$ 434.7	434.7
Pre-tax Gain	156.4	156.4
Divestiture transaction costs	13.3	13.3
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Osurnia
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	140.5	140.5
Pre-tax Gain	93.1	93.1
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Vecoxan
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	55.1	55.1
Pre-tax Gain	37.1	37.1
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Capstar
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	95.9	95.9
Pre-tax Gain	25.5	25.5
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Drontal and Profender
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	140.6	140.6
Pre-tax Gain	0	0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Other Immaterial Divestitures
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross Cash Proceeds	2.6	2.6
Pre-tax Gain	$ 0.7	$ 0.7

Acquisitions and Divestitures_7

Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) - Worldwide rights to Osurnia and U.S. rights to Capstar - Held for Sale $ in Millions	Dec. 31, 2019USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories	$ 10.6
Other intangibles, net	61.2
Property and equipment, net	0.2
Total assets held for sale	72
Deferred taxes	(1.4)
Total liabilities held for sale	$ (1.4)

Asset Impairment, Restructuri_3

Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restructuring charges:
Severance and other costs	$ 130.2	$ 10.4	$ 131.2	$ 9.6
Facility exit costs	0	0	0.7	0
Acquisition related charges:
Transaction and integration costs	131.1	46.1	318.5	99.6
Non-cash and other items:
Asset impairment	0	10.2	3.5	14.2
Asset write-down	0.9	10.5	3.2	10.5
Gain on sale of fixed assets	0	0	(3.8)	0
Settlements and other	0	0	3.1
Total expense	$ 262.2	$ 77.2	$ 456.4	$ 133.9

Asset Impairment, Restructuri_4

Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) - Bayer Animal Business $ in Millions	9 Months Ended
	Sep. 30, 2020USD ($)positioncountry
Restructuring Cost and Reserve [Line Items]
Expected number of positions eliminated | position	900
Number of countries expected to eliminate positions | country	40
Minimum
Restructuring and Related Activities [Abstract]
Expected total restructuring charges	$ 190
Restructuring Cost and Reserve [Line Items]
Expected total restructuring charges	190
Maximum
Restructuring and Related Activities [Abstract]
Expected total restructuring charges	210
Restructuring Cost and Reserve [Line Items]
Expected total restructuring charges	$ 210

Asset Impairment, Restructuri_5

Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Restructuring Reserve [Roll Forward]
Balance at beginning of period	$ 20.9	$ 44.4
Charges	132.6	40.7
Reserve adjustments	(0.8)	(10.2)
Cash paid	(16.2)	(20.8)
Balance at end of period	136.5	54.1
Facility exit costs
Restructuring Reserve [Roll Forward]
Balance at beginning of period	5.4	9.3
Charges	0.7	20.7
Reserve adjustments	0	0
Cash paid	(1.2)	(2)
Balance at end of period	4.9	28
Severance
Restructuring Reserve [Roll Forward]
Balance at beginning of period	15.5	35.1
Charges	131.9	20
Reserve adjustments	(0.8)	(10.2)
Cash paid	(15)	(18.8)
Balance at end of period	$ 131.6	$ 26.1

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished products	$ 797.1	$ 402.9
Work in process	664.1	603.2
Raw materials and supplies	167	83.9
Total	1,628.2	1,090
Decrease to LIFO cost	(31.1)	(39.3)
Inventories	$ 1,597.1	$ 1,050.7

Equity - Narrative (Details)

Equity - Narrative (Details)	Jan. 23, 2020USD ($)shares	Jan. 22, 2020USD ($)trading_day$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Class of Stock [Line Items]
Number of shares sold in public offering | shares	25,000,000
Proceeds after underwriting discounts and commissions	$ 767,500,000
Net proceeds			$ 6,140,100,000	$ 2,355,000,000
Tangible Equity Unit (TEU)
Class of Stock [Line Items]
Number of shares sold in public offering | shares		11,000,000
Offering price (usd per share) | $ / shares		$ 50
Proceeds after underwriting discounts and commissions		$ 528,500,000
Tangible Equity Unit (TEU) | Minimum
Class of Stock [Line Items]
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares		14,300,000
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares		$ 32
Tangible Equity Unit (TEU) | Maximum
Class of Stock [Line Items]
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares		17,200,000
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares		$ 38.40
5.00% Tangible Equity Units | Senior Notes
Class of Stock [Line Items]
Interest rate on debt component		5.00%
Number of consecutive trading days | trading_day		20
2.75% Senior Amortizing Notes | Senior Notes
Class of Stock [Line Items]
Interest rate on debt component		2.75%
Net proceeds		$ 79,200,000
Quarterly cash installment per amortizing note		0.6250
Initial principal amount		7.2007
First installment payment per amortizing note		$ 0.6528
Common Stock Offering
Class of Stock [Line Items]
Number of shares sold in public offering | shares		22,700,000
Offering price (usd per share) | $ / shares		$ 32
Over-Allotment Option
Class of Stock [Line Items]
Number of shares sold in public offering | shares		2,300,000
Tangible Equity Unit (TEU)
Class of Stock [Line Items]
Offering price (usd per share) | $ / shares		$ 50

Equity - Schedule of Stockholde

Equity - Schedule of Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 23, 2020	Jan. 22, 2020	Sep. 30, 2020	Sep. 30, 2019
Class of Stock [Line Items]
Gross proceeds			$ 1,219.9	$ 0
Net proceeds	$ 767.5
Equity Component
Class of Stock [Line Items]
Price per share (usd per share)		$ 42.80
Gross proceeds		$ 470.8
Less: Issuance costs		18.4
Net proceeds		$ 452.4
Debt Component
Class of Stock [Line Items]
Price per share (usd per share)		$ 7.20
Gross proceeds		$ 79.2
Less: Issuance costs		3.1
Net proceeds		$ 76.1
Tangible Equity Unit (TEU)
Class of Stock [Line Items]
Price per share (usd per share)		$ 50
Gross proceeds		$ 550
Less: Issuance costs		21.5
Net proceeds		$ 528.5
Tangible Equity Unit (TEU) | Minimum
Class of Stock [Line Items]
Applicable Market Value (usd per share)		$ 32
Settlement rate		130.21%
Tangible Equity Unit (TEU) | Maximum
Class of Stock [Line Items]
Applicable Market Value (usd per share)		$ 38.40
Settlement rate		156.25%

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2020	Jan. 22, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term debt, gross	$ 6,241.2
Unamortized debt issuance costs	(101.5)		$ (16.8)
Total debt	6,140.1		2,355
Less current portion of long-term debt	553.6		24.5
Total long-term debt	5,586.5		2,330.5
Credit facility | Term loan B credit facility
Debt Instrument [Line Items]
Long-term debt, gross	4,175		0
Credit facility | Term credit facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 0		371.4
Senior Notes | 3.912% Senior Notes due 2021
Debt Instrument [Line Items]
Interest rate	3.912%
Long-term debt, gross	$ 500		500
Senior Notes | 4.272% Senior Notes due 2023
Debt Instrument [Line Items]
Interest rate	4.272%
Long-term debt, gross	$ 750		750
Senior Notes | 4.900% Senior Notes due 2028
Debt Instrument [Line Items]
Interest rate	4.90%
Long-term debt, gross	$ 750		750
Senior Notes | TEU amortizing notes
Debt Instrument [Line Items]
Interest rate		5.00%
Long-term debt, gross	66.2		0
Other obligations
Debt Instrument [Line Items]
Long-term debt, gross	$ 0.4		$ 0.4

Debt - Narrative (Details)

Debt - Narrative (Details)	Sep. 25, 2020USD ($)	Aug. 01, 2020USD ($)	Jan. 31, 2020USD ($)	Jan. 23, 2020USD ($)shares	Jan. 22, 2020USD ($)$ / sharesshares	Oct. 31, 2020USD ($)	Sep. 30, 2020USD ($)numberOfCovenants	Sep. 24, 2018USD ($)
Debt Instrument [Line Items]
Debt financing costs							$ 90,200,000
Unused commitment fee		$ 13,800,000
Number of shares issued (in shares) | shares				25,000,000
Proceeds after underwriting discounts and commissions				$ 767,500,000
Tangible Equity Unit (TEU)
Debt Instrument [Line Items]
Number of shares issued (in shares) | shares					11,000,000
Price per share (usd per share) | $ / shares					$ 50
Proceeds after underwriting discounts and commissions					$ 528,500,000
Equity Component
Debt Instrument [Line Items]
Price per share (usd per share) | $ / shares					$ 42.80
Proceeds after underwriting discounts and commissions					$ 452,400,000
Debt Component
Debt Instrument [Line Items]
Price per share (usd per share) | $ / shares					$ 7.20
Proceeds after underwriting discounts and commissions					$ 76,100,000
Credit Facility | Term loan B credit facility
Debt Instrument [Line Items]
Number of financial covenants | numberOfCovenants							0
Debt repaid, principal	$ 100,000,000
Debt extinguishment loss	$ 2,100,000
Credit Facility | Term loan B credit facility | Bayer Animal Business
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		4,275,000,000
Outstanding debt		$ 4,175,000,000
Debt maturity term		7 years
Credit Facility | Term loan B credit facility | LIBOR | Bayer Animal Business
Debt Instrument [Line Items]
Basis spread on variable rate		1.75%
Credit Facility | Revolving credit facility
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity		$ 750,000,000						$ 750,000,000
Debt maturity term		5 years
Drawdown		$ 200,000,000
Debt issuance costs		$ 9,200,000
Number of financial covenants | numberOfCovenants							2
Required ratio of pro forma net leverage and pro forma adjusted EBITDA							7.71
Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than)							2
Credit Facility | Revolving credit facility | Subsequent Event
Debt Instrument [Line Items]
Drawdown						$ 250,000,000
Credit Facility | Revolving credit facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		1.50%
Credit Facility | Revolving credit facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%
Credit Facility | Term Loan Facility
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity								500,000,000
Debt repaid			$ 372,400,000
Debt repaid, principal			371,400,000
Debt repaid, interest			1,000,000
Debt extinguishment loss			$ 800,000
Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount								$ 2,000,000,000
Senior Notes | TEUs
Debt Instrument [Line Items]
Debt instrument, face amount					$ 550,000,000
Interest rate					5.00%
Partial payment on principal and interest							$ 14,100,000

Debt - Maturity of Long-Term De

Debt - Maturity of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Fourth quarter of 2020	$ 16.8
2021	567.6
2022	68
2023	797.5
2024	40.3
2025	39.9
Thereafter	4,711.1
Total obligations and commitments	6,241.2
Unamortized debt issuance costs and other obligations	(101.1)
Total debt	$ 6,140.1	$ 2,355

Financial Instruments and Fai_3

Financial Instruments and Fair Value - Narrative (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2018CHF (SFr)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jul. 31, 2019USD ($)	Jul. 18, 2019USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity method investments		$ 21,700,000		$ 21,700,000			$ 18,800,000
Loss on cash flow hedge, net of tax benefit		7,500,000	$ 0	67,400,000	$ 0
Tax benefit on loss on cash flow hedge		2,200,000		19,600,000
Expected reclassification from accumulated other comprehensive loss		28,000,000		28,000,000
Aratana
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Maximum aggregate contingent payment									$ 12,000,000
Prevtec
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Maximum aggregate contingent payment								$ 16,300,000
Decrease of fair value of contingent consideration liability				2,100,000
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notional amount (USD, CHF)		$ 1,496,900,000		1,496,900,000			$ 861,200,000
Cross-currency fixed interest rate swap | Net Investment Hedging | Designated as Hedging Instrument
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notional amount (USD, CHF) | SFr	SFr 750,000,000
Term of contract	5 years
Cash benefit for liquidation				35,100,000
Interest included in cash benefit				$ 2,400,000
Forward-starting interest rate contracts designated as cash flow hedges | Cash Flow Hedging | Designated as Hedging Instrument
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notional amount (USD, CHF)						$ 4,050,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value - Summary of Fair Value Information (Details) - Recurring - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt - senior notes	$ 0	$ 0
TEU amortizing note	0
Term loan B	0
Long-term debt - term credit facility		0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt - senior notes	(2,186.7)	(2,120.6)
TEU amortizing note	(66.2)
Term loan B	(4,068)
Long-term debt - term credit facility		(371.4)
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt - senior notes	0	0
TEU amortizing note	0
Term loan B	0
Long-term debt - term credit facility		0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt - senior notes	(2,000)	(2,000)
TEU amortizing note	(66.2)
Term loan B	(4,175)
Long-term debt - term credit facility		(371.4)
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt - senior notes	(2,186.7)	(2,120.6)
TEU amortizing note	(66.2)
Term loan B	(4,068)
Long-term debt - term credit facility		(371.4)
Prepaid expenses and other | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0	0
Prepaid expenses and other | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	10.7	0.8
Prepaid expenses and other | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0	0
Prepaid expenses and other | Carrying Amount | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	10.7	0.8
Prepaid expenses and other | Fair Value | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	10.7	0.8
Other current liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0	0
Other current liabilities | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	(7.6)	(1.1)
Other current liabilities | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0	0
Other current liabilities | Carrying Amount | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	(7.6)	(1.1)
Other current liabilities | Fair Value | Foreign exchange contracts not designated as hedging instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	(7.6)	(1.1)
Other noncurrent liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Other noncurrent liabilities | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Other noncurrent liabilities | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	(2.6)	(4.7)
Other noncurrent liabilities | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	(2.6)	(4.7)
Other noncurrent liabilities | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	(2.6)	(4.7)
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward-starting interest rate contracts designated as cash flow hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate contracts designated as net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)		0
Other noncurrent assets | Significant Other Observable Inputs (Level 2) | Forward-starting interest rate contracts designated as cash flow hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	(87)
Other noncurrent assets | Significant Other Observable Inputs (Level 2) | Cross currency interest rate contracts designated as net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)		2.3
Other noncurrent assets | Significant Unobservable Inputs (Level 3) | Forward-starting interest rate contracts designated as cash flow hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	0
Other noncurrent assets | Significant Unobservable Inputs (Level 3) | Cross currency interest rate contracts designated as net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)		0
Other noncurrent assets | Carrying Amount | Forward-starting interest rate contracts designated as cash flow hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	(87)
Other noncurrent assets | Carrying Amount | Cross currency interest rate contracts designated as net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)		2.3
Other noncurrent assets | Fair Value | Forward-starting interest rate contracts designated as cash flow hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)	$ (87)
Other noncurrent assets | Fair Value | Cross currency interest rate contracts designated as net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities)		$ 2.3

Financial Instruments and Fai_5

Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) - Cross-currency fixed interest rate swap - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Not Designated as Hedging Instrument | Other Operating Income (Expense)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Net gain (loss) on derivative instruments	$ (2.3)	$ 10.1	$ 19.4	$ 8.8
Designated as Hedging Instrument | Net Investment Hedging
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain, net of tax	0	18.5	24	23.9
Designated as Hedging Instrument | Interest Expense | Net Investment Hedging
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Amount offsetting interest expense	$ 0	$ 6.2	$ 6.2	$ 18.4

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	Jun. 26, 2020	Sep. 30, 2020
Leases [Abstract]
Sale leaseback proceeds	$ 55.1
Sale leaseback initial lease term	15 years
Sale leaseback gain		$ 45.6
Sale leaseback lease payments		$ 27.8

Income Taxes - Provision for Ta

Income Taxes - Provision for Taxes on Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (74)	$ (22.5)	$ (116.6)	$ 5.1
Effective tax rate	35.40%	179.70%	32.90%	6.20%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (74)	$ (22.5)	$ (116.6)	$ 5.1
Effective tax rate	35.40%	179.70%	32.90%	6.20%
Income Tax Contingency [Line Items]
Income tax (benefit) expense	$ (74)	$ (22.5)	$ (116.6)	$ 5.1
Novartis Animal Health
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	(14)
Income Tax Contingency [Line Items]
Income tax (benefit) expense	$ (14)

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Liabilities related to litigation	$ 0	$ 0

Geographic Information - Narrat

Geographic Information - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)	Sep. 30, 2019	Sep. 30, 2020USD ($)segment	Sep. 30, 2019	Dec. 31, 2019USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment			1
Concentration Risk [Line Items]
Accounts receivable	$ 762.3		$ 762.3		$ 816.9
Product Sales
Concentration Risk [Line Items]
Accounts receivable	$ 78.1		$ 78.1		$ 90.5
Customer Concentration Risk | Revenue | Single Customer
Concentration Risk [Line Items]
Concentration risk (as a percent)	11.70%	15.90%	11.90%	13.40%

Geographic Information - Revenu

Geographic Information - Revenue by Selected Geographic Area Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 889.6	$ 771.3	$ 2,133.6	$ 2,284
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	421.5	388.2	969.5	1,167.1
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 468.1	$ 383.1	$ 1,164.1	$ 1,116.9

Geographic Information - Long-l

Geographic Information - Long-lived Assets by Selected Geographic Area Information (Details) - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1,665.7	$ 1,147.1
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	942.6	709.8
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	243.7	39.7
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	206.3	192.6
Other foreign countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 273.1	$ 205

Earnings Per Share (Details)

Earnings Per Share (Details) - shares shares in Millions	Aug. 01, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Subsidiary, Sale of Stock [Line Items]
Common stock equivalents included in weighted average diluted shares outstanding (in shares)			1.5		1
Antidilutive shares not included in calculating diluted earnings per share (in shares)			0.1		0.1
Bayer Animal Business
Subsidiary, Sale of Stock [Line Items]
Shares issued to previous shareholders upon closing (in shares)	72.9	72.9		72.9
Common Stock Offering
Subsidiary, Sale of Stock [Line Items]
Weighted average commons shares included in calculation of basic earnings per share (in shares)		25		25
Tangible Equity Unit (TEU)
Subsidiary, Sale of Stock [Line Items]
Weighted average commons shares included in calculation of basic earnings per share (in shares)		14.3		14.3

Related Party Agreements and _3

Related Party Agreements and Transactions - Amounts Due From/(Due To) Lilly (Details) - Lilly - USD ($) $ in Millions	Sep. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Total payable to Lilly	$ (11.3)	$ (16.4)
TSA
Related Party Transaction [Line Items]
Total payable to Lilly	1.1	10.5
Other activities
Related Party Transaction [Line Items]
Total payable to Lilly	(1.7)	(15.8)
Local country asset purchases
Related Party Transaction [Line Items]
Total payable to Lilly	$ (10.7)	$ (11.1)

Related Party Agreements and _4

Related Party Agreements and Transactions - Narrative (Details) - USD ($) shares in Millions, $ in Millions	Aug. 01, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Restricted cash and payable		$ 10.7	$ 10.7	$ 11.1	$ 11.1
Bayer Animal Business
Related Party Transaction [Line Items]
Interest percentage		15.50%	15.50%
Bayer Animal Business
Related Party Transaction [Line Items]
Shares issued to previous shareholders upon closing (in shares)	72.9	72.9	72.9
Bayer
Related Party Transaction [Line Items]
Related party, accounts payable		$ 9.8	$ 9.8
Bayer | Leases
Related Party Transaction [Line Items]
Operating lease liabilities		60	60
Operating lease, right-of-use asset		60	60
Bayer | TSA
Related Party Transaction [Line Items]
Other liabilities due to affiliate		2.7	2.7
Bayer | Local country asset purchases
Related Party Transaction [Line Items]
Due from related party		233.6	233.6
Due to related party		233.6	233.6
Bayer | Other activities
Related Party Transaction [Line Items]
Receivable from, payable (to) related party		(20.4)	(20.4)
Lilly
Related Party Transaction [Line Items]
Receivable from, payable (to) related party		(11.3)	(11.3)		(16.4)
Cost of stock-based compensation plans				$ 5.1
Lilly | TSA
Related Party Transaction [Line Items]
Receivable from, payable (to) related party		1.1	$ 1.1		10.5
Mark-up rate			7.00%
Lilly | Local country asset purchases
Related Party Transaction [Line Items]
Receivable from, payable (to) related party		(10.7)	$ (10.7)		(11.1)
Lilly | Other activities
Related Party Transaction [Line Items]
Receivable from, payable (to) related party		$ (1.7)	$ (1.7)		$ (15.8)